Medical management of metastatic medullary thyroid cancer

Response to Sunitinib in Medullary Thyroid Cancer

(2013) Fergal C. Kelleher et al.   ANNALS OF INTERNAL MEDICINE

Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor

(2013) Ronald P. DeMatteo et al.   ANNALS OF SURGERY

An update on clinical trials of targeted therapies in thyroid cancer

(2013) Sigurdis Haraldsdottir et al.   CURRENT OPINION IN ONCOLOGY

Targeted therapy in thyroid cancer

(2013) Iain J. Nixon et al.   Current Opinion in Otolaryngology & Head and Neck Surgery

Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study

(2013) J A A Meijer et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer

(2013) Valentina De Falco et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib

(2013) K Mayer et al.   LEUKEMIA

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase

(2013) Luca Mologni et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer

(2013) Alan L. Ho et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer

(2013) Steven I. Sherman   ORAL ONCOLOGY

Translational Research in Endocrine Surgery

(2013) Scott K. Sherman et al.   Surgical Oncology Clinics of North America

Sorafenib in metastatic thyroid cancer

(2012) Jaume Capdevila et al.   ENDOCRINE-RELATED CANCER

Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

(2012) P.-Y. Salaun et al.   JOURNAL OF NUCLEAR MEDICINE

BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment

(2012) Ralph P. Tufano et al.   MEDICINE

Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)

(2012) Françoise Kraeber-Bodéré et al.   TUMOR BIOLOGY

New treatment modalities in advanced thyroid cancer

(2011) E. Kapiteijn et al.   ANNALS OF ONCOLOGY

Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies

(2011) David S. Hong et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Completing the Arc: Targeted Inhibition of RET in Medullary Thyroid Cancer

(2011) Yariv Houvras   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

(2011) Steven Aller et al.   PEDIATRIC BLOOD & CANCER

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

(2010) L. L. Carr et al.   CLINICAL CANCER RESEARCH

Rapid Response to Sorafenib in Metastatic Medullary Thyroid Carcinoma

(2010) K. Frank-Raue et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Bruce G. Robinson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Neoadjuvant Treatment of Unresectable Medullary Thyroid Cancer With Sunitinib

(2010) James M. Cleary et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

(2010) Elaine T. Lam et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant external beam radiation for medullary thyroid carcinoma

(2010) Steve R. Martinez et al.   JOURNAL OF SURGICAL ONCOLOGY

Targeting the RET Pathway in Thyroid Cancer

(2009) S. A. Wells et al.   CLINICAL CANCER RESEARCH

Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis

(2009) Johannes A. A. Meijer et al.   CLINICAL ENDOCRINOLOGY

Thoracic metastasectomy for thyroid malignancies☆☆☆

(2009) John Roland Porterfield et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

(2009) Martin J. Schlumberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

(2009) Richard T. Kloos (Chair) et al.   THYROID

Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors

(2008) M. A. Izquierdo et al.   CLINICAL CANCER RESEARCH

Long-term prognosis of medullary thyroid carcinoma

(2008) G. Rendl et al.   CLINICAL ENDOCRINOLOGY

Postoperative radiotherapy for advanced medullary thyroid cancer—Local disease control in the modern era

(2008) David L. Schwartz et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma

(2008) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

(2008) Vandana Gupta-Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

(2008) D. Hong et al.   MOLECULAR CANCER THERAPEUTICS

Long-term Outcome of Reoperations for Medullary Thyroid Carcinoma

(2008) Elizabeth Fialkowski et al.   WORLD JOURNAL OF SURGERY

Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study

(2007) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer

(2007) Nathan A. Pennell et al.   THYROID

Use of Capecitabine in Refractory Metastatic Medullary Thyroid Carcinoma

(2007) Carlos Eduardo Paiva et al.   THYROID